Literature DB >> 21680613

Osteoporosis: yesterday, today and tomorrow.

Nancy E Lane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21680613      PMCID： PMC3116213          DOI： 10.1093/rheumatology/ker147

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  14 in total

Review 1.  How to manage falls in community dwelling older adults: a review of the evidence.

Authors:  Claire McKay; Kathryn E Anderson
Journal:  Postgrad Med J       Date:  2010-04-20       Impact factor: 2.401

Review 2.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

3.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

4.  The diagnosis of osteoporosis.

Authors:  J A Kanis; L J Melton; C Christiansen; C C Johnston; N Khaltaev
Journal:  J Bone Miner Res       Date:  1994-08       Impact factor: 6.741

5.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

6.  Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Authors:  Eric C Buxton; Wei Yao; Nancy E Lane
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

Review 7.  Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects.

Authors:  Cedric Annweiler; Manuel Montero-Odasso; Anne M Schott; Gilles Berrut; Bruno Fantino; Olivier Beauchet
Journal:  J Neuroeng Rehabil       Date:  2010-10-11       Impact factor: 4.262

8.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

9.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

10.  Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.

Authors:  Henry G Bone; Michael R McClung; Christian Roux; Robert R Recker; John A Eisman; Nadia Verbruggen; Carolyn M Hustad; Carolyn DaSilva; Arthur C Santora; B Avery Ince
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.